Last reviewed · How we verify
JMKX000623
At a glance
| Generic name | JMKX000623 |
|---|---|
| Sponsor | Jemincare |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A DDI Study of JMKX000623 and Metformin Hydrochloride (PHASE1)
- Evaluate the Efficacy and Safety of JMKX000623 in Participants With Diabetic Peripheral Neuropathic Pain (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- JMKX000623 CI brief — competitive landscape report
- JMKX000623 updates RSS · CI watch RSS
- Jemincare portfolio CI